Synovial membrane-derived mesenchymal stem cell (SM-MSC)

Synovial membrane-derived mesenchymal stem cells (SM-MSCs) are a population of multipotent progenitor cells residing within the synovial lining of diarthrodial joints, characterized by their high proliferative capacity and exceptional chondrogenic potential (De Bari et al., 2001, PubMed: 11710618). Unlike mesenchymal stem cells derived from bone marrow or adipose tissue, SM-MSCs exhibit a significantly greater propensity for cartilage formation, making them a primary candidate for regenerative medicine strategies targeting osteoarthritis and focal cartilage defects (Shirasawa et al., 2006, PubMed: 16449230). These cells function through both direct differentiation into chondrocytes to physically repair tissue and the secretion of immunomodulatory paracrine factors that reduce joint inflammation (Sakaguchi et al., 2005, PubMed: 15751020). While SM-MSCs are not a conventional molecular drug target, they are the focus of advanced cell therapy protocols where they are harvested, expanded, and re-implanted, or manipulated using growth factors like TGF-beta and BMPs to enhance their therapeutic efficacy (Sekiya et al., 2002, PubMed: 12115450). Clinical challenges include ensuring the quality of expanded cells and preventing adverse outcomes such as ectopic calcification or synovial hyperplasia during therapeutic application (Mochizuki et al., 2006, PubMed: 16700065).

Other names

Synovium-derived mesenchymal stem cellSynovial MSCSMSCSynovial membrane-derived multipotent progenitor cell

Paracrine secretion of trophic factors and direct differentiation into specialized mesenchymal lineages (primarily chondrocytes) to facilitate tissue repair and suppress local inflammation.